News
-
Clinovo Launches New CDISC Express Service Packages
1/11/2012
Clinovo, the leading clinical data solution provider in the San Francisco Bay Area, announced recently the launch of three CDISC Express service packages, adapted to different needs and different budgets.
-
Clinovo Completes Phase I Study Builds In Only 3 1/2 Weeks
1/11/2012
Clinovo, the leading clinical data solution provider in the San Francisco Bay Area, announced the successful project completion for a fast-growing medical device company’s Phase I clinical trial.
-
Kedem Pharmaceuticals Engages A FDA Compliant Contract Formulation Development Company For The Production Of KDM-1102 Clinical Materials
1/5/2012
Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company's second lead therapeutic drug.
-
Boehringer Ingelheim Completes Patient Entry For Phase III Trial Programme In Hepatitis C
12/22/2011
Boehringer Ingelheim recently announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).
-
Cara Therapeutics Initiates Phase I Study With Oral Formulation Of Novel Peripherally-Acting Kappa Opioid Agonist
11/23/2011
Cara Therapeutics, Inc. today announced the initiation of a first-in-man Phase I clinical trial of an oral formulation of its peptide-based, kappa opioid agonist, CR845, in healthy volunteers.
-
Virginia G. Piper Cancer Center & TGen Form Drug Development Collaboration With Cedars-Sinai
11/10/2011
The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.
-
St. Jude Children's Research Hospital Discovery Aided Quest For Adult Cancer Drug
9/30/2011
A drug recently approved by the U.S. Food and Drug Administration for treatment of an adult cancer targets a malfunctioning gene discovered more than a decade earlier at St. Jude Children's Research Hospital.
-
DaVita Clinical Research Launches New Advisory Committee Preparation Services
9/28/2011
DaVita Clinical Research (DCR), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, will launch their new Advisory Committee Preparation Services at the 2011 Regulatory Affairs Professionals Society (RAPS): The Regulatory Convergence.
-
Quotient Announces Agreement With Phico Therapeutics And First Application Of RapidFACT For Nasal Delivery
9/14/2011
Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), recently announced an agreement with UK-based biotech, Phico Therapeutics (Phico).
-
Cytokinetics Announces Phase I And Phase IIa Clinical Trial Results For Omecamtiv Mecarbil Published In The Journal Lancet
8/23/2011
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of results from two clinical trials of omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet.
This website uses cookies to ensure you get the best experience on our website. Learn more